Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
Technion Biomed Engineers Assess Novel Approach to Treating Type 2 Diabetes
Error: Contact form not found.
by JNS.org
A diabetes patient testing their blood sugar level. Photo: Reversing Your Diabetes Today via Wikicommons.
JNS.org – A novel approach to treating Type 2 diabetes is being developed at the Technion–Israel Institute of Technology in Haifa.
The disease, caused by insulin resistance and the reduction of cells’ ability to absorb sugar, is characterized by increased blood-sugar levels. Its long-term complications include heart disease, strokes, damage to the retina that can result in blindness, kidney failure and poor blood flow in the limbs that may lead to amputations.
It is currently treated by a combination of lifestyle changes, medication and insulin injections, but ultimately is associated with a 10-year reduction in life expectancy.
Ph.D. student Rita Beckerman from the Stem Cell and Tissue Engineering Laboratory in the Technion’s Faculty of Biomedical Engineering, who conducted the research with professor Shulamit Levenberg, presented a novel treatment approach, using an autograft of muscle cells engineered to take in sugar at increased rates. Mice treated in this manner displayed normal blood sugar levels for months after a single procedure.
